Effective April 1, 2025, Stelara (ustekinumab) will be a nonformulary medication, and all non-Medicare patients will need to switch to an ustekinumab biosimilar for covered treatment.
Carle Health has announced after careful consideration, as of January 1, 2026, our health plans will cease operating all lines of business except for Medicare Advantage.
FLASH: Recent Calls regarding select codes removed from Prior Authorization requirements effective 1/1/2025
Endless Thanks As another new year moves forward, with spring already in our sights, we want to extend our gratitude to you, your staff and all your colleagues for all that you do for our members. We know their health is in great hands because of your expertise. We’re fortunate to have you as a partner, as together we bring wellness to everyone who counts on us. Today – and every day – we offer our deepest, heartfelt thanks.